A federal judge heard closing arguments Friday in a case that will determine whether the top U.S. publisher, Penguin Random House, can purchase the fourth largest publisher, Simon & Schuster.
Over the course of the three-week antitrust trial, the Department of Justice narrowed its case on authors’ paid book advances of $250,000 or above, a data-based proposed anticipated bestseller market that it says may be harmed if the $2.175 billion dollar deal goes through.
But defense attorneys insist the $250,000 cutoff is problematic because it is solely based on the idea that one less publisher may “trigger” competition harm in the already ailing publishing industry, which is led by just five companies, known as “The Big Five.”
As defense attorney Daniel Petrocelli tells it, the government’s proposed market does not fit the Justice Department’s horizontal merger guidelines and it fails to consider “brown shoe” industry evaluation factors, such as publishers poaching from other publishers, which speaks to its arbitrariness.
Prosecutors grilled the global CEO of Penguin Random House, Markus Dohle, during the trial and he conceded there are “enough” books in the $250,000 tier of book advances that “would make a difference” in U.S. market share for Penguin Random House, and the merger would “cement” the company’s position as the nation’s dominant publisher.
But Petrocelli told the judge in closings that government is “really relying” on the correlation between author advances and predicted book sales, but there is nothing “qualitatively” different between a $100 advance and a $100,000 advance.
“General correlation does nothing in and of itself to prove the government’s proposed market,” he said.
The only reason we are here, he said, is because “the government created artificial concentration to create artificial harm.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Appoints Law Firms to Lead Consumer Antitrust Litigation Against Apple
Dec 22, 2024 by
CPI
Epic Health Systems Seeks Dismissal of Antitrust Suit Filed by Particle Health
Dec 22, 2024 by
CPI
Qualcomm Secures Partial Victory in Licensing Dispute with Arm, Jury Splits on Key Issues
Dec 22, 2024 by
CPI
Google Proposes Revised Revenue-Sharing Limits Amid Antitrust Battle
Dec 22, 2024 by
CPI
Japan’s Antitrust Authority Expected to Sanction Google Over Monopoly Practices
Dec 22, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand